Livemint: July 25, 2016
Hyderabad: Glenmark Pharmaceuticals Ltd on Monday said the US Food and Drug Administration (FDA) has granted it final approval to launch an ointment for specific skin conditions in the US.
The topical steroid, triamcinolone acetonide ointment, 0.5%, marketed by US-based Perrigo Co., is used to treat skin conditions such as eczema and psoriasis. It had sales of around 4.4 million dollars for the 12-month period ending May, Glenmark said, quoting US-based healthcare information provider IMS Health.
Glenmark said its current portfolio consists of 116 products authorised for distribution in the US and 61 abbreviated new drug applications pending approval with the USFDA.
“In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio,” the company said.
Shares of Glenmark rose 0.22% and were trading at Rs.867 on the BSE at 11:50am, while the benchmark Sensex gained 0.45% and was trading at 27,926.38 points.
Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.